Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Shun YamamotoKengo NagashimaTakeshi KawakamiSeiichiro MitaniMasato KomodaYasushi TsujiNaoki IzawaKentaro KawakamiYoshiyuki YamamotoAkitaka MakiyamaKentaro YamazakiToshiki MasuishiTaito EsakiTakako Eguchi NakajimaHiroyuki OkudaToshikazu MoriwakiNarikazu BokuPublished in: BMC cancer (2021)
In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents.